Alessandria del Carretto, Italy
Alessandria del Carretto, Italy

Time filter

Source Type

News Article | February 15, 2017
Site: www.prweb.com

March is colorectal cancer awareness month and, if you’re over 50 or if you’re younger than 50 but have a family history, it is a very good time to undergo a screening colonoscopy. Colorectal cancer is the second most common cancer in the United States and is also one of the most preventable. Most colorectal cancers develop from noncancerous polyps and removing these polyps can markedly reduce your risk of getting the disease. Ohio Gastroenterology & Liver Institute (http://www.ohiogi.com) cares about the community and strongly believes in the importance of colorectal screening. That is why OGI are donating 100 referrals to receive the HyGIeaCare® Prep which will allow patients to achieve excellent preparation of the colon by a method which is much more easily tolerated than traditional oral bowel preps. The HyGIeaCare® Center is located at 4746 Montgomery Rd. Suite 200 - Cincinnati, OH (call 513-569-1343 for scheduling) and features the HyGIeaCare® System which is approved by the U.S. Food and Drug Administration (FDA) and which effectively cleans the bowel using a gentle infusion of warm, gravity-flow filtered water. “At Ohio GI, we pride ourselves on personalized, professional, prompt, specialized care for each and every patient,” said Pradeep Bekal MD, a gastroenterologist from Ohio GI. “Screening for colorectal cancer saves lives and having an excellent preparation is key to effective colonoscopy. I urge the community to call and schedule their colonoscopy and benefit from our exclusive offering of HyGIeaCare® Prep.” The convenience of HyGIeaCare prep for colonoscopy At the HyGIeaCare® Center, the prep is performed in a clean and comfortable environment. Our trained technician leads the patient to a private room where he or she is seated on an ergonomic basin. The technician walks the patient through the procedure, which routinely takes less than one hour. A small, sterile, disposable nozzle is easily inserted about an inch into the rectum and a gentle stream of warm water flows into the bowel, loosening stool and causing the intestine to contract allowing for the comfortable, odorless and discreet evacuation of the colon. Water continues to gently flow until the technician determines the colon has been sufficiently cleansed. The HyGIeaCare Prep replaces traditional oral preps for colonoscopy and is performed immediately prior to the scheduled colonoscopy. It is safe, comfortable and preferred over oral preps. For more information about HyGIeaCare® please go to: http://www.hygieacare.com Ohio Gastroenterology and Liver Institute (“Ohio GI”) Ohio GI (http://www.ohiogi.com ) is the largest and most comprehensive private Gastroenterology practice servicing Greater Cincinnati, Fairfield and Northern Kentucky. Ohio GI combines unparalleled personalized expertise with prompt appointments in geographically convenient offices and related Endoscopy Centers. As the area’s Gastroenterology innovation leader Ohio GI introduces cutting edge therapies and medical technologies. Ohio GI offers consultative and procedural expertise by employing physicians who sub-specialize in important areas such as Inflammatory Bowel Disease (IBD), Pancreatic Diseases, Hepatology / Liver Diseases, Women’s Digestive Health and Esophageal / Swallowing Disorders as well as screening colonoscopy and preventative health management. Ohio GI monitors a variety of quality metrics (eg, cecal intubation rates, colonoscopy withdrawal times, adenoma detection rates) to ensure that its physicians exceed national benchmark standards. Ohio GI operates a major national Medical Research Center and has participated in many pivotal trials which have led to the approval of new treatments for Crohns Disease, Ulcerative Colitis, Irritable Bowel Syndrome, GERD, Hepatitis B, Hepatitis C, Duodenal Ulcers and Gastric Ulcers. The physicians of Ohio GI are also actively engaged in Greater Cincinnati’s local and regional medical community as well as with a variety of national Gastroenterology societies. About HyGIeaCare, Inc.(http://www.hygieacare.com) Chairman and CEO Gavriel (Gabi) Meron - the founder and former CEO of Given Imaging, the Company that successfully brought the PillCam to the world - partnered with Texas-based Lifestream Purification Systems to form HyGIeaCare, Inc. to bring the HyGIeaCare FDA-cleared Prep System and procedure exclusively to the GI world. The goal of HyGIeaCare is to provide unique services and solutions to gastroenterologists to deliver better GI outcomes for their patients and their practice through HyGIeaCare Centers to be established in the US and throughout the world.


(PRLEAP.COM)– According to a new series of reports on the European dental implant fixture and final abutment market by iData Research ( www.idataresearch.com ), a growing prevalence of local manufacturers and increasingly cost-sensitive consumer demographic is contributing to overall price deprecation and the declining market share of premium implants. Historically, premium dental implant companies have dominated the competitive landscape in Europe but have recently faced rising competition from the value and discount brands."The increasing pricing pressure in the market has led premium implant companies to levy significant discounts on their products in order to remain competitive," explains Jeffery Wong, Strategic Analyst Manager at iData Research. "Regions with a larger presence of value and discount brands have been impacted most heavily and this limiting effect on overall growth is expected to continue over the next several years."However, despite persistent price depreciation, both mature and relatively underdeveloped markets continue to generate moderate levels of unit growth, thereby mitigating the net effect on market growth. For example, the key development within the final abutment market is the rapidly increasing uptake of patient-individualized CAD/CAM solutions and focus on digital dentistry. Additionally, a growing number of local laboratories have emerged to produce and distribute CAD/CAM abutments, making them more accessible. Market growth within these segments will be driven by increased penetration in relatively underdeveloped markets, such as France and the United Kingdom.Recent improvements in manufacturing capability and product affordability have resulted in rapid adoption of the CAD/CAM abutments, which offer significant progression in aesthetics and clinical outcomes, relative to the stock and custom cast abutments. It is expected that the European market will continue to adopt CAD/CAM technology, generating consistent growth for the final abutment market.Straumann is the leading competitor in the European dental implant fixture and final abutment market. Straumann's success can be attributed to its comprehensive product portfolio comprising traditional implants and abutments, as well as offerings that include ceramic implants, full arch restorations, CAD/CAM abutments and regenerative dental biomaterials. Furthermore, Straumann has continually reinforced its leading position in the market with strategic investments in value and discount implant companies such as Neodent, Biodenta, Medentika, MegaGen and Anthogyr. Continued expansion through strategic acquisitions and partnerships will aid Straumann in maintaining its leading position in the European dental implant market. Dentsply Sirona holds the second leading position in the market, benefitting from a strong presence across all market segments. Other leading competitors include Nobel Biocare, Zimmer Biomet, CAMLOG, Sweden & Martina, Medentis, MIS Implants and BEGO among others.More on the dental implant market in Europe can be found in a series of reports published by iData Research entitled the European Market Report Suite on Dental Implant Fixtures and Final Abutments . The suite covers reports on the following markets: dental implant fixtures, final abutments, treatment planning software and surgical guides.The iData report series on dental implants covers the U.S., Japan, South Korea, Australia, China,India, Brazil, Argentina, Mexico and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about dental implant market data or procedure data, register online or email us at info@idataresearch.net for a European Market Report Suite on Dental Implant Fixtures and Final Abutments brochure and synopsis.iData Research ( www.idataresearch.com ) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Dental Prosthetics, Dental Lasers, Dental Materials, Dental Bone Graft Substitutes, Dental Implants, Dental CAD/CAM, Dental Operatory Equipment, Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Vascular Access, Endoscopy, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics, Ophthalmics and more.Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. We have built a reputation and earned our clients' trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success.


News Article | February 15, 2017
Site: www.eurekalert.org

PITTSBURGH (February 14, 2017) ... Dysphagia, or swallowing disorders, affects nearly one in 25 adults, especially the elderly and those who have suffered a stroke or neurological disease, and results in approximately 150,000 hospitalizations annually. A patient's risk for dysphagia is first diagnosed by screening, and may require an endoscopy or fluoroscopy for further evaluation. However, some patients who aspirate do so silently, causing doctors to misdiagnose. To develop an improved screening method for dysphagia, the National Science Foundation awarded a researcher at the University of Pittsburgh's Swanson School of Engineering a CAREER Award through the NSF's Division of Chemical, Bioengineering, Environmental, and Transport Systems. Ervin Sejdic, assistant professor of electrical and computer engineering, received a five-year, $549,139 award to further research using high-resolution vibration and sound recordings that would help doctors diagnose dysphagia and assist patients in improving how to properly swallow while eating or drinking. The CAREER program is the NSF's most prestigious award for junior faculty who exemplify outstanding research, teaching, and their integration. Dr. Sejdic, who began this research while a postdoctoral associate at the University of Toronto and Holland Bloorview Kids Rehabilitation Hospital, Canada's largest children's rehabilitation hospital, explained that an improved, non-invasive method to detect dysphagia could help to reduce patient risk and hospitalization. "By using modern data analytics we can compare and contrast the sound and vibrations of normal swallowing against patients with dysphagia," Dr. Sejdic explained. "This allows us to understand how the airway normally protects itself during swallowing to avoid aspiration, and how this is affected during dysphagia, without the need for surgery or intubation." According to Dr. Sejdic, patients with silent dysphagia may pass a traditional screening, which increases the potential for choking and suffocation. Analyzing the sounds and vibrations from the neck would not only reduce the incidence of silent aspiration, but also the need for conservative recommendations that limit eating and drinking for individuals with neurological disabilities such as multiple sclerosis or ALS. In addition to developing the technology, the award will allow Dr. Sejdic to collaborate with speech language pathologists to develop an online learning module to further education and outreach throughout the U.S. He would also like to utilize the data analysis to design a mobile device that would help patients while eating, but notes that possibility is several years in the future. "Endoscopy and fluoroscopy are still the gold standard for detecting dysphagia," Dr. Sejdic said. "For now we're not looking at replacing them but rather enhancing and improving the screening process."


— Market Research Future published a Half-Cooked Research Report on Global Alzheimer’s Disease Diagnostic Market. Global Alzheimer’s Disease Diagnostic Market is expected to grow at a CAGR of 10% during the period 2016 to 2022 Alzheimer’s is a type of dementia which causes failure of the functioning of the brain. This disease damages the areas which is responsible for the thinking, problem solving and behavior process. According to the Alzheimer’s association, more than 5 million are living with Alzheimer’s and one out of three seniors dies with the Alzheimer’s or any another type of dementia. One of the most common early symptoms of Alzheimer's is difficulty remembering newly learned information. As the Alzheimer's advances through the brain it leads to increasingly severe symptoms which include bafflement, mood and behavior swings, deepening confusion about events, time and place; unfounded thoughts about family, friends and professional caregivers and more serious memory loss and behavior changes; and difficulty speaking, swallowing and walking. There are different types of tests to diagnose the symptoms of the Alzheimer’s which includes Mini Mental State Exam (MMSE) this tests will help to know whether there are problems with the areas of brain involved in learning, memory, thinking, or planning skills. Other one is brain imaging which includes CT scan, Magnetic Resonance Imaging (MRI); Neuropsychological Testing and genetic tests which provide information regarding the incorrect linking of the genes which causes Alzheimer’s among others. • Eli Lilly and Company (UK), • TauRx (Republic of Singapore), • Alector LLC (US), • Accera, Inc. (US), • Treventis Corporation (US), • Neuro-Bio Ltd (UK), • Cognition Therapeutics Inc. (US) Global Alzheimer’s Disease Diagnostic Market has been evaluated as a growing market and it is expected that the market will touch high growth figures in future. Factors such rising efforts on research and development by the players to treat Alzheimer’s disease and the introduction of the blockbuster drugs into the market to cure the disease will drive the growth of the market. Global Alzheimer’s Disease Diagnostic Market is expected to grow with CAGR of 10% during the forecasted period. Access the market data and market information presented through more than 85 market data tables and 25 figures spread over 90 numbers of pages of the project report “Alzheimer’s Disease Diagnostic Market - Forecast to 2022” • Globally North America is the largest market for Alzheimer’s disease as they deploy the most advanced techniques and increasing demand for the cost effective products. • Europe is the second-largest market for Alzheimer’s disease. • Asia pacific region is expected to be fastest growing region in Alzheimer’s disease diagnostic market due to increasing spending on healthcare infrastructure and acceptance of the advanced products in this region. • On the basis of Type which comprises of Early-Onset Alzheimer's, Late-Onset Alzheimer's, Familial Alzheimer’s Disease and Others. • On the basis of Diagnostic Tests Market is segmented into Genetic Testing, Neurological Exam, Mini-Mental State Exam (MMSE), Brain Imaging and Others. • On the basis of End Users Market is segmented into Clinics, Hospitals, Diagnostic Centers and Others. Global Cancer Diagnostics Market Information: by Type (Biopsy Based, Endoscopy Based, Imaging Procedure, Tumor Biomarkers and others), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma and others), End User (Diagnostic Center, Clinic, Hospital, Research Institutes and others) - Forecast to 2022 https://www.marketresearchfuture.com/reports/cancer-diagnostics-market At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. For more information, please visit https://www.marketresearchfuture.com


(PRLEAP.COM)– iData Research ( www.idataresearch.com ) recently conducted a face-to-face survey for catheterization lab, structural heart and coronary stents during the 2016 Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington, DC. Participants included cardiac surgeons, interventional cardiologists, interventional radiologists and general practitioners. Results have shown that clinical outcomes are the main deciding factor for respondents when choosing which brand of coronary stents to use. Respondents gave reasons for choosing a particular device, including price, availability of devices and existing relationships."This latest report is a global survey regarding demographic trends, concerns, experiences and preferences among cardiologists," explains Dr. Kamran Zamanian, CEO of iData. "Our iData team found answers to the questions posed by major cardiovascular device manufacturers regarding what they wanted to learn from the attendees of TCT 2016."Respondents came from a total of 57 countries. Each country has been subsequently categorized into six distinctive geographical regions: North America, Latin America, Europe, the Middle East, Africa and Asia. Within these regions, the United States, Brazil and Argentina represented the top three countries with the most respondents.The Global Survey on Catheterization Labs, Structural Heart and Coronary Stents by iData Research includes responses for the following questions*:*Results for each question are sorted globally and by regioniData's Global Physician Surveys are conducted by highly trained moderators with years of experience in applying iData's rigorous methodology to ensure balanced responses and to elicit keen insight from physicians, surgeons, specialists and other medical professionals. iData's Global Physician Surveys are used to garner brand awareness, product preferences, message feedback and positioning. iData's Physician Surveys allow the inclusion of a diverse range of medical professionals in broader geographical areas. They also eliminate group bias and allow for interactive one-on-one feedback as well as flexibility to expose the respondent to interactive or static media.iData Research ( www.idataresearch.com ) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Vascular Access, Endoscopy, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics, Ophthalmics, Dental Operatory Equipment and more.


NORWALK, Connecticut, 27 febbraio 2017 /PRNewswire/ -- Mederi Therapeutics ha annunciato oggi la pubblicazione di una meta analisi di 28 studi, che rappresentano 2468 pazienti sottoposti alla Terapia Stretta per il trattamento della malattia da reflusso gastroesofageo (MRGE). Lo studio dal titolo "Systematic Review and Meta-Analysis of Controlled and Prospective Cohort Efficacy Studies of Endoscopic Radiofrequency for Treatment of Gastroesophageal Reflux Disease (Riesame sistematico e meta analisi degli studi controllati e prospettici dell'efficacia per coorti della radiofrequenza endoscopica per il trattamento della malattia da reflusso gastroesofageo" è stato pubblicato in Surgical Endoscopy. Tra gli autori ci sono Ronnie Fass, MD, responsabile dello Esophageal and Swallowing Center (Centro esofageo e per la deglutizione), Director of Gastroenterology and Hepatology (Direttore di gastroenterologia ed epatologia) presso il Metro Health Medical Center e Professore presso la Case Western University, e l'esperto di statistica Frederick Cahn, PhD, direttore di Strategie Biomediche. L'autore principale, il dott. Ronnie Fass ha commentato, "Questa analisi completa ha combinato la nostra esperienza clinica con l'esperienza statistica del dott. Cahn per produrre il riesame più completo e oggettivo dei dati disponibili al momento. I risultati hanno dimostrato che Stretta è una terapia clinicamente efficace e sicura per la MRGE." Il dott. Cahn, che vanta oltre 30 anni di esperienza nel settore sanitario, ha sottolineato gli standard elevati del presente studio. "L'analisi completa degli studi, sulla base della metodologia consigliata da Cochrane, ha dimostrato che sono di qualità elevata con un basso rischio di distorsione. Abbiamo anche rilevato una elevata quantità di risultati positivi nell'ampio numero di studi. I punti di forza di questa meta analisi comprendono: follow-up fino a 10 anni (25 mesi in media), un gran numero di soggetti (2468), e l'inclusione di 28 studi, dati che collocano questa meta analisi nell'1% dei riesami e delle meta analisi sistematiche di alto livello." Il dott. Fass ha spiegato, "I risultati di questo studio evidenziano che Stretta riduce in modo significativo i sintomi della MRGE, e al tempo stesso si riflette sui parametri fisiologici, quali ad esempio la riduzione dell'esposizione agli acidi, e la guarigione delle esofagiti erosive." La malattia da reflusso gastroesofageo (MRGE) è la condizione in cui si ha il reflusso del contenuto dello stomaco nell'esofago con sintomi quali il bruciore di stomaco e il rigurgito. Questo reflusso si verifica a causa della debolezza della barriera muscolare tra lo stomaco e l'esofago. La cura più comune della MRGE è rappresentata da cure mediche, di solito inibitori della pompa protonica, tuttavia. il 30 percento circa dei pazienti non ha un sollievo sufficiente da queste cure mediche, e altri sono preoccupati dai rischi associati a lungo termine. Stretta applica livelli bassi di energia in radiofrequenza (RF) al muscolo dello sfintere esofageo inferiore. Il trattamento ispessisce il muscolo dello sfintere, riducendo la cedevolezza del tessuto e il rilassamento transiente del muscolo dello sfintere esofageo inferiore, migliorando la barriera tra lo stomaco e l'esofago e migliorando i sintomi della MRGE. Stretta è un trattamento non chirurgico endoscopico che offre un'alternativa notevolmente più sicura e meno invasiva rispetto a quella di interventi chirurgici anti reflusso, e inoltre libera da cure mediche a cui sottoporsi per tutta la vita. I dati economici sulla salute, pubblicati di recente, dimostrano che il trattamento della MRGE con Stretta ha portato a importanti risparmi nei costi per gli utenti soggetti al pagamento, rispetto alle cure mediche a lungo termine o agli interventi chirurgici. "La combinazione della nostra nuova meta analisi e dei dati economici fornisce ulteriore supporto all'uso di Stretta come trattamento per i pazienti affetti da MRGE," ha aggiunto Fass. Bob Knarr, Amministratore Delegato di Mederi ha spiegato l'impatto di questo studio. "Questa approfondita analisi dati conferma che Stretta è sicuro ed efficace nel trattamento della MRGE. Questo nuovo studio combinato con i dati economici fanno di Stretta una scelta vincente per i pazienti e per gli utenti soggetti al pagamento, migliorando la qualità delle cure e riducendo i costi al tempo stesso."


LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global pulmonary endoscopy devices market is expected to grow at a CAGR of more than 4% during the forecast period. This research report titled ‘Global Pulmonary Endoscopy Devices Market 2017-2021’ provides an in-depth analysis of the market in terms of revenue and emerging market trends. This report also includes an up to date analysis and forecasts for various market segments and all geographical regions. According to Barath Palada, a lead analyst at Technavio for medical devices research, “The advances in technology for pulmonary endoscopes has transformed the diagnosis and evaluation of abnormal thoracic findings, which include masses, pleural diseases, lung nodules, and mediastinal lymphadenopathy.” Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more. The market research analysis categorizes the global pulmonary endoscopy devices market into three major product segments. They are: The bronchoscope, also known as a pulmonary endoscope is a medical device inserted into the patient's body either through nose or mouth into the lungs. The endoscope camera or the light source at the tip of the endoscope lets the physician or medical professional view the target site. Most endoscopic procedures are performed in the physician's office or an outpatient setting. The benefits of endoscopy include low cost, speedy recovery, reduction in the need for open surgery procedures, and less time needed for diagnosis. The endoscopic instruments consist of devices used during the procedure, including cameras, video monitors, light sources, video recorders, video processors, electrosurgical generators, and insufflators. The average lifespan of endoscopic equipment is from six to seven years. Thus, the replacement of old equipment with new advanced devices is the major contributor to revenue generation in this segment. Also, innovations in endoscopy visualization systems, such as the development of high-definition and ultra-high definition video systems have enhanced the visualization of the patient's anatomy. “Thus, endoscopic instruments and accessories is a high-volume segment that involves constant replacement, making it a steady revenue stream for the manufacturers,” says Barath. In order to ensure sustained proficiency, optimal performance, and reduced morbidity, endoscopy systems require annual servicing for better performance. The revenue in this segment is usually created through annual maintenance contracts, part replacements, and ad-hoc repairs. As the market for pulmonary endoscopy devices reaches maturity, there will be an increase in demand for high-quality services. Services need to be provided by reputed vendors in the market that have brand value along with safety and efficacy. The growing demand for training is also expected to drive the segment growth, owing to the limited availability of skilled surgeons. The top vendors highlighted by Technicon’s healthcare and life sciences market research analysts in this report are: Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like medical imaging, oncology, and urology devices. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently. Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies. Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users. If you are interested in more information, please contact our media team at media@technavio.com.


NORWALK, Connecticut, 27 février 2017 /PRNewswire/ -- Mederi Therapeutics a annoncé aujourd'hui la publication d'une méta-analyse de 28 études, représentant 2 468 patients qui ont bénéficié de la thérapie Stretta dans le traitement du reflux gastro-œsophagien (GERD). Cette étude, intitulée « Systematic Review and Meta-Analysis of Controlled and Prospective Cohort Efficacy Studies of Endoscopic Radiofrequency for Treatment of Gastroesophageal Reflux Disease », a été publiée dans la revue Surgical Endoscopy. Parmi ses auteurs figurent le docteur Ronnie Fass, MD, chef du centre de l'œsophage et de la déglutition, directeur de gastro-entérologie et d'hépatologie au Metro Health Medical Center et professeur à la Case Western University, et l'expert en statistiques Frederick Cahn, PhD, principal de Biomedical Strategies. Pour l'auteur en chef, le docteur Ronnie Fass : « Cette analyse exhaustive a fait intervenir notre savoir-faire clinique et mobilisé en même temps l'expérience en statistiques du docteur Cahn afin de réaliser l'examen le plus approfondi et le plus objectif des données actuellement disponibles. Les résultats montrent que Stretta constitue une thérapie cliniquement efficace et sûre dans le traitement du GERD ». Le Dr Cahn, qui a à son actif plus de 30 années d'expérience des soins de santé, a relevé le niveau très élevé de cette étude. « Une analyse approfondie des études, en faisant appel à la méthodologie recommandée par Cochrane, a démontré qu'elles étaient d'une grande qualité et présentaient un faible risque d'erreur systématique. Nous avons également constaté une convergence des résultats positifs sur l'ensemble des études. Parmi les atouts de cette méta-analyse figurent : jusqu'à 10 années de suivi (moyenne de 25 mois), un nombre élevé de sujets (2 468) et l'inclusion de 28 études, ce qui place cette méta-analyse dans le 1 % de tête des examens systématiques et des méta-analyses ». Pour le Dr Fass : « Les résultats de cette étude montrent que Stretta atténue sensiblement les symptômes du GERD tout en impactant les paramètres physiologiques, comme la réduction de l'exposition à l'acide et la guérison de l'œsophagite ulcérative ». Le reflux gastro-œsophagien (GERD) est une affection dans laquelle le contenu de l'estomac repasse dans l'œsophage, ce qui engendre des symptômes comme des brûlures d'estomac et de la régurgitation. Ce reflux survient en raison d'une faiblesse du muscle qui sépare l'estomac de l'oesophage. Le traitement du GERD fait le plus souvent appel à des médicaments, habituellement des PPI, mais environ 30 pour cent des patients ne sont pas soulagés avec ces médicaments, tandis que d'autres s'inquiètent de leurs effets à long terme. Stretta applique une faible quantité d'énergie de radiofréquence (RF) sur le muscle du sphincter œsophagien inférieur (LES). Ce traitement permet d'épaissir le muscle du sphincter, ce qui réduit l'élasticité des tissus et les relâchements passagers du LES, renforçant ainsi la barrière entre l'estomac et l'oesophage, et atténuant les symptômes du GERD. Stretta est un traitement endoscopique non chirurgical qui offre une solution nettement plus sûre et moins invasive en remplacement d'une chirurgie anti-reflux et qui évite aux personnes concernées de prendre des médicaments tout au long de leur vie. Des données économiques sur la santé récemment publiées montrent que traiter le GERD avec Stretta permet aux établissements payeurs de réaliser d'importantes économies de coûts par rapport à une médication de longue durée ou à une chirurgie. « La combinaison de notre nouvelle méta-analyse et des données économiques milite encore davantage en faveur de l'emploi de Stretta dans le traitement des patients atteints de GERD », ajoute Fass. Bob Knarr, PDG de Mederi, a expliqué l'impact de cette étude : « Cette analyse de données en profondeur confirme que Stretta est sûr et efficace dans le traitement du GERD. Cette nouvelle étude, en plus des données économiques, font de Stretta une solution idéale tant pour les patients que pour les organismes payeurs, améliorant la qualité de vie tout en réduisant les coûts ». A PROPOS DE MEDERI® ET DE STRETTA® Mederi fabrique des dispositifs médicaux innovants qui font appel à l'énergie RF non ablative pour traiter les maladies digestives. Au terme de plus de 40 études avec un suivi à long terme jusqu'à 10 ans, il a été démontré que Stretta était sûr et efficace dans le traitement du GERD. Stretta est disponible dans le monde entier. Mederi a fourni son appui pour l'analyse statistique de cette étude. Pour de plus amples informations, rendez-vous sur stretta-therapy.com ou formez le +1-855-855-3639.


(PRLEAP.COM)According to a new series of reports on the Australia market for vascular access devices by iData Research ( www.idataresearch.com ), the use of peripherally inserted central catheters (PICCs) has grown significantly at the expense of central venous catheter (CVCs). The PIVC segment is growing rapidly as new technologies enter the market to focus on reducing infection rates and make PIVCs safer and easier to use. Nurse-led placement of PICCs has been a catalyst for the increasing adoption of PICCs which significantly lowers overall procedural cost. The combination of these factors will result in overall unit sales growth in the PICCs market.While the markets for traditional devices such as PICCs and CVCs are maturing, companies are actively investing in the development of new technological features that have increased average selling prices (ASPs) for these devices. New technologies are expected to have a significant impact on the vascular access device market. The competition in this market has spurred companies to differentiate their products in order to gain market share. This has consistently led to unique, premium-priced products."The more significant technological advancements will be in electrocardiogram (ECG) tip location," explains Dr. Kamran Zamanian, CEO of iData. "In addition, the increasing use of ultrasound has led to significant growth in the use of PICCs. Increasingly, ultrasound is being used for placement of PIVCs."Previously, implantable ports were thought to be a high potential market, owing to product innovations such as power-injectable implantable ports, dual lumen ports and arm ports. However, multi-lumen implantable ports have not sold as well as previously anticipated and the prices for power-injectable implantable ports have been decreasing dramatically. The price decreases of power-injectable implantable ports have been occurring as those devices become the standard of care in Australia and as manufacturers attempt to keep and gain market share by making their power-injectable devices more economically appealing.C. R. Bard is the leading competitor in the total Australian vascular access market. They are the strongest in the implantable port and PICC market, but also hold a significant share in the port needles market. The company has been extremely aggressive in their marketing and acquisition strategies in the vascular access market. In addition, the company continues to lead the way with new technologies, such as power-injectable devices. C. R. Bard takes advantage of the crossover between market segments and has been able to increase their presence in the rapidly growing complementary markets.Becton Dickinson is the second leading competitor, offering a wide variety of safety products. This company continues to innovate through the introduction of new products such as the Nexiva™ closed system PIVC. Additional competitors in this market include Teleflex Medical, B. Braun, Smiths Medical, Cook Medical, Medcomp, Angiodynamics, Medtronic and Baxter among others. B. Braun continues to invest in the PIVC market, with a particular focus on the safety PIVC segment.More on the vascular access device market in Australia can be found in a report suite published by iData Research entitled the Australia Market Report Suite for Vascular Access Devices and Accessories . The suite covers reports on the following markets: implantable ports, port needles, central venous catheters (CVCs), peripherally inserted central catheters (PICCs), peripheral intravenous catheters (PIVCs) and dialysis catheters.The iData report series on vascular access devices covers the U.S., Japan, South Korea, Australia, India, China, Brazil and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about vascular access device market data or procedure data, register online or email us at info@idataresearch.net for an Australia Market Report Suite for Vascular Access Devices and Accessories brochure and synopsis.iData Research ( www.idataresearch.com ) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Vascular Access, Endoscopy, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics, Ophthalmics, Dental Operatory Equipment and more.


Market Research Future has a half cooked research report on Endoscopy Devices Market. The Global Endoscopy Devices Market is expected to reach USD 33.6 million during the period 2016 to 2022 from USD 28.7 million in 2016. The major players of this market are that hole the largest market shares are: Global Endoscopy Devices Market has been examined as a swiftly growing market and expected to grow at a tremendous rate. Globally there is huge demand for endoscopy device in various regions. The increasing growth in endoscopy procedures is influencing the market to grow and thus increasing demand for advanced technology endoscopy devices. The major factors that will enhance the Endoscopy Devices Market include intrinsic factors that will improve endoscopy instrumentation such as optics, electronics and computers moreover external factors: non‐technical, non‐scientific, non‐endoscopic and developments in other medical fields will furthermore help the market to grow. These high procedure volumes will in turn generate huge demand for endoscopy devices because hospitals and clinics will have need of additional devices to treat the patients. Access the market data and market information presented through more than 50 market data tables and figures spread over 80 numbers of pages of the project report “Global Endoscopy Devices Market Research Report -Forecast to 2022” Endoscopy Devices Market has been segmented on the basis of type which comprises of rigid, and flexible. Rigid holds the largest market share for global endoscopy market by type. On the basis of application, market is segmented into arthroscopes, bronchoscope, colposcopy, laparoscopy, gastroscopy and others. Furthermore on the basis of end user the market is segmented into hospitals, clinics, academics and others. Regional Analysis Globally North America is the largest market for Endoscopy Devices Market. This large share of North American market for endoscopy devices is mainly due to increasing advancement in healthcare technology and endoscopy devices. Europe is the second-largest market for endoscopy devices. Asia pacific region is expected to be fastest growing region in Endoscopy Devices Market with increasing aging population in the region and thus demand for the market is growing at a rapid pace. Make an Enquiry of your Interest @ https://www.marketresearchfuture.com/enquiry/1967 At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members. For more information, please visit https://www.marketresearchfuture.com/reports/endoscopy-devices-market

Loading Endoscopy collaborators
Loading Endoscopy collaborators